PAC-IC-SAOS Obstructive Sleep Apnea Syndrome and Ventricular Function (PAC-IC-SAOS)

Impact of the Obstructive Sleep Apnea Syndrome Treatment and Ventricular Function in Heart Failure Patients Undergoing Coronary Artery Bypass Surgery or Other Coronary Reperfusion

The aim of this clinical trial is to evaluate the effect of obstructive sleep apnea syndrome (OSAS) treatment in heart failure patients following coronary artery bypass graft (CABG) surgery or other coronary reperfusion.

This clinical trial is a double-blind, randomized, placebo-controlled study. The first objective is to evaluate the influence of continuous positive airway pressure (CPAP) treatment for OSAS on the ventricular function improvement in heart failure patients, in comparison with OSA patients treated with sham CPAP. This treatment will be instaurated just after the coronary reperfusion surgery Secondary objectives : Evaluation of the effect of CPAP treatment on the endothelial function Evaluation of the effect of CPAP treatment on systemic inflammation Evaluation of the effect of CPAP treatment on oxidative stress, Evaluation of the effect of CPAP treatment on insulin resistance, after the coronary reperfusion surgery, in comparison with OSA patients treated with sham CPAP and non apneic control patients, with heart failure. Assessment of the impact of nocturnal desaturation level on the vascular reactivity and atherosclerosis of mammary vessels collected during surgery. Assessment of the impact of nocturnal desaturation level on the oxidative stress, inflammation and insulin sensitivity on abdominal and epicardiac adipose tissue collected during surgery.

Heart Failure, Arteriosclerosis of Coronary Artery Bypass Graft or Other Coronary Reperfusion, Sleep Apnea, Obstructive

Obstructive sleep apneas syndrome, Continuous positive airway pressure treatment, Heart failure, Coronary reperfusion surgery

This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.

This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.

Percent of ventricular function recovery (left ventricular ejection fraction (LVEF)) improvement conferred by CPAP post-operative treatment

Assessment of CPAP effect on the endothelial function, after the surgery in comparison with sham CPAP treated patient with heart failure and OSAS.

Assessment of CPAP effect on the endothelial function, after the surgery in comparison with sham CPAP treated patient with heart failure and OSAS.

Assessment of the impact of nocturnal desaturation level on the vascular atherosclerosis of mammary vessels collected only during CABG surgery.

Assessment of the impact of nocturnal desaturation level on the oxidative stress, inflammation and insulin sensitivity of the abdominal and epicardiac adipose tissue collected during surgery.

Assessment of the impact of nocturnal desaturation level on the vascular reactivity of mammary vessels collected during surgery.

Assessment of CPAP effect on the systemic inflammation and oxidative stress, the insulin resistance, after the surgery in comparison with sham CPAP treated patients with heart failure and OSAS.

Inclusion Criteria: Coronary Artery Bypass Surgery or other coronary reperfusion Heart failure patient: with altered left ventricular ejection fraction by ultrasonography (≤ 50% in 2D) or in 3D Exclusion Criteria: Aortic or mitral valvular replacement Aortic surgery Triple stimulator implanted less than 6 months ago Patient already treated for a SAOS syndrome Patient with a central sleep apnea syndrome Patient with malignant evolutive pathology Pregnant or lactating women